- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04500353
Routine Or Selective Application of a Face Mask for Preterm Infants at Birth: the ROSA Trial (ROSA)
A Randomised Trial of Routine or Selective Application of a Face Mask for Preterm Infants at Birth
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Newly born babies have fluid-filled lungs that they must quickly aerate after birth. Compared to infants born at term, preterm babies have greater difficulty in establishing and maintaining aeration of their lungs; this leaves them at increased risk of developing respiratory distress syndrome (RDS). Infants who develop RDS are treated with nasal continuous positive airway pressure (CPAP), and may progress to treatment with surfactant and mechanical ventilation, in the Neonatal Intensive Care Unit (NICU).
The Neonatal Task Force of the International Liaison Committee on Resuscitation (ILCOR) makes recommendations on the treatment of infants at birth. ILCOR recommends assessing the breathing and heart rate (HR) of all newborns, and:
- Giving positive pressure ventilation (PPV) to babies who have a HR < 100bpm, gasping or apnoea
- Considering giving CPAP to babies who have laboured breathing or persistent cyanosis
Most preterm infants breathe spontaneously at birth. Despite this, the majority of preterm infants have a facemask applied for respiratory support immediately after birth, usually before the HR has been determined. Clinicians presumably do this to give early support to infants they believe are at high risk of developing RDS in an attempt to prevent or lessen the severity of the disease.
There is little evidence that giving preterm infants prophylactic nasal CPAP may be superior to supportive care with oxygen. A study that compared nasopharyngeal CPAP to supportive care with oxygen performed before antenatal steroids were routinely given found no difference in the rate of development of RDS with the application of CPAP. Two more recent studies did not show that early application of nasal CPAP reduced the rate of intubation or treatment with surfactant. In these studies CPAP was given by nasal prongs and was started at 15 - 30 minutes of life, not immediately with a facemask. There is no evidence that facemask CPAP immediately after birth prevents or reduces the severity of RDS.
Application of a face mask has been demonstrated to inhibit spontaneous breathing in many term infants. Cold gas flow, such as that provided by a T-piece, can inhibit spontaneous breathing in term infants. Application of a face mask for breathing support appears to inhibit breathing in a greater proportion of preterm infants. Considerable force is applied to the head when face mask PPV is given to a mannequin in the supine position.
Routinely applying a face mask for respiratory support may be unnecessary in many premature babies. It may inhibit their spontaneous breathing and result in them receiving facemask PPV more frequently in the DR. It may also affect how well they breathe in the first day of life and increase the rate of treatment with nasal CPAP in the NICU.
METHODS
RANDOMISATION AND GROUP ASSIGNMENT Participants will be randomly assigned to "SELECTIVE" or "ROUTINE" groups in a 1:1 ratio. The group assignment schedule will be generated in blocks of 4 using a random number table, and will be stratified by gestational age (23 - 27, 28 - 31+6). It will be kept on a concealed from investigators and treating clinicians. Group assignment will be written on cards and placed in sequentially numbered, sealed, opaque envelopes. Infants of multiple gestations will be randomised as individuals.
The envelopes will be contained in 2 boxes for GA strata and kept in the NICU. The next envelope in the sequence will be taken from the appropriate box and brought to the DR, where it will be opened just before delivery.
MASKING It is not possible to mask caregivers to group assignment.
INTERVENTIONS
ALL INFANTS Infants in both groups will have their umbilical cord clamped at or after 1 minute of age; they will not have a mask applied for respiratory support during this time. Infants will then be transferred to resuscitaire, placed supine under radiant heat and have a hat applied. All infants will be placed in polyethylene bag. A pulse oximeter will be placed on the right wrist.
A T-piece device (Neopuff, Fisher & Paykel Healthcare, Auckland NZ; or Dräger Resuscitaire (Drager healthcare, Lübeck, Germany) and round face mask (Fisher & Paykel Healthcare, Auckland NZ) of appropriate size for the baby will be used to give respiratory support to infants in both groups. The T-piece will have gas flow set at 8 - 10 L/min, with settings PEEP 6cmH2O, and PIP 25cmH2O. There will be an air/oxygen blender in the circuit and the FiO2 will be initially set at 30%. The FiO2 will not be adjusted before 5 minutes of age.
SELECTIVE GROUP Infants assigned to the "SELECTIVE" group will be placed supine to breathe spontaneously. If SpO2 < 70% at 5 minutes and their respiratory effort is good, they will be given give free flow oxygen (i.e. the mask will be placed in front of, but not directly in contact with, the infant's face). The FiO2 may be increased at 1 minute intervals thereafter, aiming for SpO2 ≥ 90% at 10 minutes of life.
Infants in the "SELECTIVE" group will have mask PPV if they are apnoeic or have HR < 100bpm at any time in the DR. Clinicians may consider applying facemask to give CPAP if the infants breathing is laboured (i.e. there are signs of respiratory distress - grunting, intercostal/subcostal/sternal recessions) after 5 minutes of age.
ROUTINE GROUP Infants assigned to the "ROUTINE" group will be placed supine on the resuscitaire and have facemask CPAP applied as soon as possible after they arrive. If SpO2 < 70% at 5 minutes, the FiO2 may be increased at 1 minute intervals, aiming for SpO2 ≥ 90% at 10 minutes of life.
Infants in the "ROUTINE" group will have facemask PPV if they are apnoeic or have HR < 100bpm at any time in the DR. Mask respiratory support may be withdrawn as and when desired by clinical staff.
RESUCE TREATMENT All other treatments - i.e. endotracheal intubation for PPV, chest compressions, adrenaline, volume - w ill be given at the discretion of the treating clinicians and in accordance with ILCOR recommendations.
SAMPLE SIZE ESTIMATION To show a reduction in the proportion of babies receiving PPV with routine application from 60% to 40% with selective application with 80% power and α of 0.05, the investigators need to recruit 200 infants.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Colm PF O'Donnell, PhD
- Phone Number: 3186 35316373100
- Email: codonnell@nmh.ie
Study Contact Backup
- Name: Lisa K McCarthy, PhD
- Phone Number: 35316373100
- Email: lmccarthy@nmh.ie
Study Locations
-
-
-
Dublin, Ireland, D02 YH21
- National Maternity Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Born before 32 weeks gestational age by best obstetric estimate
Exclusion Criteria:
- Infants with major congenital anomalies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Routine face mask application
Routine application of a face mask shortly after birth to deliver continuous positive airway pressure (CPAP)
|
Face mask application for CPAP and/or PPV delivery
|
Experimental: Selective face mask application
Selective application of a face mask to give positive pressure ventilation (PPV) for apnoea or bradycardia [heart rate (HR) < 100 beats per minute (bpm)] at any time in the delivery room (DR); or to give CPAP for signs of respiratory distress after 5 minutes of life
|
Face mask application for CPAP and/or PPV delivery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of participants who receive face mask PPV in the delivery room DR
Time Frame: Within 30 minutes of birth
|
The proportion of participants who receive face mask positive pressure ventilation (PPV) in the delivery room (DR)
|
Within 30 minutes of birth
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of participants who receive face mask CPAP in the first 5 minutes of life
Time Frame: 5 minutes
|
The proportion of participants who receive face mask (continuous positive airway pressure) CPAP in the first 5 minutes of life
|
5 minutes
|
The proportion of participants who receive face mask PPV in the first 5 minutes of life
Time Frame: 5 minutes
|
The proportion of participants who receive face mask PPV in the first 5 minutes of life
|
5 minutes
|
HR at 5 minutes of life
Time Frame: 5 minutes
|
Heart rate (HR) at 5 minutes of life
|
5 minutes
|
SpO2 at 5 minutes of life
Time Frame: 5 minutes
|
Oxygen saturation (SpO2) at 5 minutes of life
|
5 minutes
|
The proportion of participants who receive face mask CPAP in the DR
Time Frame: Within 30 minutes of birth
|
The proportion of participants who receive face mask CPAP in the DR
|
Within 30 minutes of birth
|
Duration of PPV in the DR
Time Frame: Within 30 minutes of birth
|
Duration of PPV in the DR
|
Within 30 minutes of birth
|
The proportion of participants who are intubated in the DR
Time Frame: Within 30 minutes of birth
|
The proportion of participants who are intubated in the DR
|
Within 30 minutes of birth
|
The proportion of participants who receive chest compressions in the DR
Time Frame: Within 30 minutes of birth
|
The proportion of participants who receive chest compressions in the DR
|
Within 30 minutes of birth
|
The proportion of participants who receive volume in the DR
Time Frame: Within 30 minutes of birth
|
The proportion of participants who receive volume in the DR
|
Within 30 minutes of birth
|
The proportion of participants who receive adrenaline in the DR
Time Frame: Within 30 minutes of birth
|
The proportion of participants who receive adrenaline in the DR
|
Within 30 minutes of birth
|
Maximum FiO2 in the DR
Time Frame: Within 20 minutes of birth
|
Maximum fraction of inspired oxygen (FiO2) in the DR
|
Within 20 minutes of birth
|
Apgar score at 5 minutes
Time Frame: 5 minutes
|
Apgar score at 5 minutes (scale 0 -10, higher scores indicate better outcome)
|
5 minutes
|
Apgar score at 10 minutes
Time Frame: 10 minutes
|
Apgar score at 10 minutes (scale 0 -10, higher scores indicate better outcome)
|
10 minutes
|
Respiratory support in transport to NICU
Time Frame: Within 45 minutes of birth
|
Respiratory support in transport to the neonatal intensive care unit (NICU)
|
Within 45 minutes of birth
|
The proportion of participants who receive NCPAP in NICU
Time Frame: Within one month
|
The proportion of participants who receive nasal CPAP in NICU
|
Within one month
|
The proportion of participants who receive endotracheal ventilation in NICU
Time Frame: Within one month
|
The proportion of participants who receive endotracheal ventilation in NICU
|
Within one month
|
The proportion of participants who receive surfactant treatment
Time Frame: Within one month
|
The proportion of participants who receive surfactant treatment
|
Within one month
|
The proportion of participants who have a pneumothorax drained
Time Frame: Within one month
|
The proportion of participants who have a pneumothorax drained
|
Within one month
|
The proportion of participants who survive free of BPD
Time Frame: Day 28 of life
|
The proportion of participants who are alive and not receiving respiratory support or supplemental oxygen on day 28 of life
|
Day 28 of life
|
The proportion of participants who receive survive free of CLD
Time Frame: 36 weeks corrected
|
The proportion of participants who are alive and not receiving respiratory support or supplemental oxygen at 36 weeks corrected age
|
36 weeks corrected
|
The proportion of participants who receive postnatal steroids
Time Frame: Through study completion, an average of 2-3 months in survivors
|
The proportion of participants who receive postnatal steroids
|
Through study completion, an average of 2-3 months in survivors
|
The proportion of participants who receive home oxygen therapy
Time Frame: Through study completion, an average of 2-3 months in survivors
|
The proportion of participants who receive home oxygen therapy
|
Through study completion, an average of 2-3 months in survivors
|
The proportion of participants who die before hospital discharge
Time Frame: Through study completion, an average of 2-3 months in survivors
|
The proportion of participants who die before hospital discharge
|
Through study completion, an average of 2-3 months in survivors
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Colm PF O'Donnell, PhD, National Maternity Hospital; University College Dublin
Publications and helpful links
General Publications
- Perlman JM, Wyllie J, Kattwinkel J, Wyckoff MH, Aziz K, Guinsburg R, Kim HS, Liley HG, Mildenhall L, Simon WM, Szyld E, Tamura M, Velaphi S; Neonatal Resuscitation Chapter Collaborators. Part 7: Neonatal Resuscitation: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2015 Oct 20;132(16 Suppl 1):S204-41. doi: 10.1161/CIR.0000000000000276. No abstract available.
- O'Donnell CP, Kamlin CO, Davis PG, Morley CJ. Crying and breathing by extremely preterm infants immediately after birth. J Pediatr. 2010 May;156(5):846-7. doi: 10.1016/j.jpeds.2010.01.007. Epub 2010 Mar 16.
- Murphy MC, McCarthy LK, O'Donnell CPF. Crying and breathing by new-born preterm infants after early or delayed cord clamping. Arch Dis Child Fetal Neonatal Ed. 2020 May;105(3):331-333. doi: 10.1136/archdischild-2018-316592. Epub 2019 May 13.
- Katheria A, Arnell K, Brown M, Hassen K, Maldonado M, Rich W, Finer N. A pilot randomized controlled trial of EKG for neonatal resuscitation. PLoS One. 2017 Nov 3;12(11):e0187730. doi: 10.1371/journal.pone.0187730. eCollection 2017.
- Kuypers KLAM, Lamberska T, Martherus T, Dekker J, Bohringer S, Hooper SB, Plavka R, Te Pas AB. The effect of a face mask for respiratory support on breathing in preterm infants at birth. Resuscitation. 2019 Nov;144:178-184. doi: 10.1016/j.resuscitation.2019.08.043. Epub 2019 Sep 12.
- Murphy MC, McCarthy LK, O'Donnell CPF. Initiation of respiratory support for extremely preterm infants at birth. Arch Dis Child Fetal Neonatal Ed. 2021 Mar;106(2):208-210. doi: 10.1136/archdischild-2020-319798. Epub 2020 Aug 26.
- Subramaniam P, Ho JJ, Davis PG. Prophylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infants. Cochrane Database Syst Rev. 2016 Jun 14;(6):CD001243. doi: 10.1002/14651858.CD001243.pub3.
- Sandri F, Ancora G, Lanzoni A, Tagliabue P, Colnaghi M, Ventura ML, Rinaldi M, Mondello I, Gancia P, Salvioli GP, Orzalesi M, Mosca F. Prophylactic nasal continuous positive airways pressure in newborns of 28-31 weeks gestation: multicentre randomised controlled clinical trial. Arch Dis Child Fetal Neonatal Ed. 2004 Sep;89(5):F394-8. doi: 10.1136/adc.2003.037010.
- Goncalves-Ferri WA, Martinez FE, Caldas JP, Marba ST, Fekete S, Rugolo L, Tanuri C, Leone C, Sancho GA, Almeida MF, Guinsburg R. Application of continuous positive airway pressure in the delivery room: a multicenter randomized clinical trial. Braz J Med Biol Res. 2014 Feb;47(3):259-64. doi: 10.1590/1414-431X20133278. Epub 2014 Jan 29.
- Chernick V, Avery ME. Response of premature infants with periodic breathing to ventilatory stimuli. J Appl Physiol. 1966 Mar;21(2):434-40. doi: 10.1152/jappl.1966.21.2.434. No abstract available.
- Dolfin T, Duffty P, Wilkes D, England S, Bryan H. Effects of a face mask and pneumotachograph on breathing in sleeping infants. Am Rev Respir Dis. 1983 Dec;128(6):977-9. doi: 10.1164/arrd.1983.128.6.977.
- Fleming PJ, Levine MR, Goncalves A. Changes in respiratory pattern resulting from the use of a facemask to record respiration in newborn infants. Pediatr Res. 1982 Dec;16(12):1031-4. doi: 10.1203/00006450-198212000-00013.
- Ramet J, Praud JP, D'Allest AM, Dehan M, Gaultier C. Trigeminal airstream stimulation. Maturation-related cardiac and respiratory responses during REM sleep in human infants. Chest. 1990 Jul;98(1):92-6. doi: 10.1378/chest.98.1.92.
- van Vonderen JJ, Kleijn TA, Schilleman K, Walther FJ, Hooper SB, te Pas AB. Compressive force applied to a manikin's head during mask ventilation. Arch Dis Child Fetal Neonatal Ed. 2012 Jul;97(4):F254-8. doi: 10.1136/archdischild-2011-300336. Epub 2011 Dec 5.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ROSA.01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infant, Premature, Diseases
-
University of MiamiPontificia Universidad Catolica de ChileTerminated
-
Aydin Adnan Menderes UniversityCompletedNursing Caries | Infant Development | Premature Infant Disease | Patient ComfortTurkey
-
University of VirginiaRecruitingDevelopment, Infant | Premature Infant DiseaseUnited States
-
Johnson & Johnson Pharmaceutical Research & Development...TerminatedInfant, Premature | Infant, Newborn
-
Istituto Giannina GasliniEubrainRecruiting
-
NICHD Neonatal Research NetworkNational Center for Research Resources (NCRR)CompletedSepsis | Infant, Small for Gestational Age | Infant, Premature | Infant, Low Birth Weight | Infant, NewbornUnited States
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaCompletedPreterm Birth | Cerebral Autoregulation | Premature Infant DiseaseItaly
-
Sun Yat-sen UniversityRecruitingPremature Infant DiseaseChina
-
Instituto Nacional de Perinatologia Isidro Espinosa...UnknownImmune System Diseases | Premature Infant Disease | Immunoglobulin DeficiencyMexico
-
Universidad de LeónCompletedPremature Birth | Premature Infant | Massage | Preterm Infant
Clinical Trials on Face mask application for CPAP and/or PPV delivery
-
Tufts Medical CenterRhode Island HospitalCompletedAcute Respiratory InsufficiencyUnited States
-
University of the Balearic IslandsCompletedCovid19 | Personal Protective EquipmentSpain
-
Irish Research Radiation Oncology GroupRecruiting
-
Centro Hospitalar do PortoCompleted
-
Umraniye Education and Research HospitalCompletedAirway Complication of Anesthesia | Congenital Subglottic StenosisTurkey
-
Changi General HospitalCompleted
-
University of Milano BicoccaCompleted
-
Mount Sinai Hospital, CanadaNot yet recruiting
-
Trakya UniversityIstanbul UniversityCompletedMaxillary Retrognathism | Rapid Maxillary Expansion | Face MaskTurkey
-
NAOS Institute of Life ScienceNot yet recruitingActinic Keratosis | Actinic Lentigo